Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Virax Biolabs Group Limited Ordinary Shares (VRAX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: VRAX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $3
1 Year Target Price $3
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -24.38% | Avg. Invested days 18 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.20M USD | Price to earnings Ratio - | 1Y Target Price 3 |
Price to earnings Ratio - | 1Y Target Price 3 | ||
Volume (30-day avg) 1 | Beta 1.64 | 52 Weeks Range 0.72 - 9.00 | Updated Date 08/15/2025 |
52 Weeks Range 0.72 - 9.00 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.62 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -238316.85% |
Management Effectiveness
Return on Assets (TTM) -64.68% | Return on Equity (TTM) -114.47% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -649748 | Price to Sales(TTM) 505.8 |
Enterprise Value -649748 | Price to Sales(TTM) 505.8 | ||
Enterprise Value to Revenue 27.27 | Enterprise Value to EBITDA 0.42 | Shares Outstanding 4341960 | Shares Floating 3676030 |
Shares Outstanding 4341960 | Shares Floating 3676030 | ||
Percent Insiders 10.08 | Percent Institutions 6.82 |
Upturn AI SWOT
Virax Biolabs Group Limited Ordinary Shares
Company Overview
History and Background
Virax Biolabs Group Limited is a biotechnology company focused on the prevention, detection, diagnosis, and treatment of viral diseases. Founded relatively recently, it focuses on developing and marketing innovative diagnostic kits and medical devices.
Core Business Areas
- Infectious Disease Diagnostics: Develops and markets diagnostic kits for various infectious diseases, including viral infections and other pathogens.
- Medical Device Development: Focuses on developing and commercializing medical devices for prevention, monitoring, and treatment of diseases.
Leadership and Structure
Information regarding the leadership team and organizational structure of Virax Biolabs Group Limited is not readily available.
Top Products and Market Share
Key Offerings
- Viral Diagnostic Kits: Virax Biolabs offers diagnostic kits for detecting viral infections. Market share data is unavailable. Competitors include Abbott Laboratories (ABT) and QuidelOrtho (QDEL).
- Medical Devices: Development and sale of medical devices. Specific market share or revenue data is not available. Competitors vary depending on the device category.
Market Dynamics
Industry Overview
The infectious disease diagnostics market is driven by rising prevalence of infectious diseases, technological advancements, and increasing demand for rapid and accurate diagnostic solutions.
Positioning
Virax Biolabs aims to position itself in the infectious disease diagnostics market by providing innovative and cost-effective diagnostic solutions, although it's a smaller player compared to established companies.
Total Addressable Market (TAM)
The global infectious disease diagnostics market is estimated to be worth billions of dollars. Virax Biolabs is a relatively small participant aiming to capture a share of this market through niche products and geographic expansion.
Upturn SWOT Analysis
Strengths
- Focus on infectious disease diagnostics
- Potential for innovative diagnostic solutions
- Agile and responsive to market needs
Weaknesses
- Limited financial resources
- Relatively small market presence
- Lack of established brand recognition
Opportunities
- Growing demand for infectious disease diagnostics
- Expansion into new geographic markets
- Strategic partnerships and collaborations
Threats
- Intense competition from established players
- Regulatory hurdles and compliance requirements
- Economic downturns affecting healthcare spending
Competitors and Market Share
Key Competitors
- Abbott Laboratories (ABT)
- QuidelOrtho (QDEL)
- Hologic (HOLX)
Competitive Landscape
Virax Biolabs faces intense competition from larger, more established companies with greater resources and brand recognition. Its success depends on developing and commercializing differentiated products and building strategic partnerships.
Growth Trajectory and Initiatives
Historical Growth: Information on historical growth trends is unavailable.
Future Projections: Projections for future growth are unavailable due to limited analyst coverage.
Recent Initiatives: Recent strategic initiatives undertaken by Virax Biolabs Group Limited are unavailable.
Summary
Virax Biolabs is a relatively new and small biotechnology company focused on infectious disease diagnostics. It faces strong competition but has the potential for growth through innovative products and strategic partnerships. Limited financial information and strong competition present significant challenges for the company. The company will need to execute its strategy to gain market share against larger players.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Market Reports
Disclaimers:
The information provided is based on available public data and analyst estimates. Actual results may vary. This is not financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Virax Biolabs Group Limited Ordinary Shares
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2022-07-21 | Chairman, CEO & Principal Accounting Officer Mr. James Foster | ||
Sector Healthcare | Industry Biotechnology | Full time employees 19 | Website https://viraxbiolabs.com |
Full time employees 19 | Website https://viraxbiolabs.com | ||
Virax Biolabs Group Limited, a biotechnology company, distributes diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of T cell in Vitro Diagnostics. The company offers various in-vitro diagnostics test kits comprising respiratory, pregnancy and fertility, infectious diseases, sti, drugs of abuse, oncology, cardiac, women's health, other test kits under the ViraxClear brands; and rapid and molecular tests for small animal veterinary diagnostics under the ViraxVet brand. It also provides ViraxImmune, a T cell In vitro diagnostic device and wellness mobile application; and service, such as antibody engineering, custom peptides, protein sequencing, vaccine efficacy testing, immunology lab services, kits and reagents. In addition, the company is involved in research and development activities; and provision of procurement, warehousing, product development, and staffing management services. It serves research organizations, corporations, independent laboratories, large hospital systems and public and private institutions, as well as distributor customers. The company operates in the United Kingdom, the United States, and China. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was founded in 2013 and is headquartered in Lanarkshire, the United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.